Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01328821 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499
A Phase 1 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01328821 is a Phase 1 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT01328821, a Phase 1 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CTP-499 following single dose administration.
Interventions
- DRUG CTP-499
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01328821
The ClinicalTrials.gov registry entry for NCT01328821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTP-499 is the first listed.
NCT01328821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01328821 about?
NCT01328821 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CTP-499 following single dose administration.
What is the current status of trial NCT01328821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2011-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01328821?
The interventions under investigation include: CTP-499 (DRUG).
Who is sponsoring clinical trial NCT01328821?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.